ALLR

Allarity Therapeutics NasdaqGM:ALLR Stock Report

Last Price

US$1.24

Market Cap

US$12.3m

7D

11.7%

1Y

n/a

Updated

17 Aug, 2022

Data

Company Financials +
ALLR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

ALLR Stock Overview

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

Allarity Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Allarity Therapeutics
Historical stock prices
Current Share PriceUS$1.24
52 Week HighUS$18.20
52 Week LowUS$1.06
Beta0
1 Month Change11.71%
3 Month Change-24.39%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-88.19%

Recent News & Updates

Shareholder Returns

ALLRUS BiotechsUS Market
7D11.7%-2.0%1.1%
1Yn/a-23.0%-9.0%

Return vs Industry: Insufficient data to determine how ALLR performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ALLR performed against the US Market.

Price Volatility

Is ALLR's price volatile compared to industry and market?
ALLR volatility
ALLR Average Weekly Movement20.8%
Biotechs Industry Average Movement12.3%
Market Average Movement7.6%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: ALLR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: ALLR's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200413James Cullemhttps://www.allarity.com

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Allarity Therapeutics, Inc. Fundamentals Summary

How do Allarity Therapeutics's earnings and revenue compare to its market cap?
ALLR fundamental statistics
Market CapUS$12.33m
Earnings (TTM)-US$28.21m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALLR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$28.22m
Earnings-US$28.21m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.84
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio6.0%

How did ALLR perform over the long term?

See historical performance and comparison